Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Altered pathways of keratinization, extracellular matrix generation, angiogenesis, and stromal stem cells proliferation in patients with systemic sclerosis.
Spinella A, Lo Tartaro D, Gibellini L, de Pinto M, Pinto V, Bonetti E, Lolli F, Lattanzi M, Lumetti F, Amati G, De Santis G, Cossarizza A, Salvarani C, Giuggioli D. Spinella A, et al. Among authors: lattanzi m. J Scleroderma Relat Disord. 2023 Jun;8(2):151-166. doi: 10.1177/23971983221130145. Epub 2022 Oct 17. J Scleroderma Relat Disord. 2023. PMID: 37287944 Free PMC article.
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ, Sarfaty M, Teo MY, Ratna N, Duzgol C, Funt SA, Lee CH, Aggen DH, Regazzi AM, Chen Z, Lattanzi M, Al-Ahmadie HA, Brannon AR, Shah R, Chu C, Lenis AT, Pietzak E, Bochner BH, Berger MF, Solit DB, Rosenberg JE, Bajorin DF, Iyer G. Guercio BJ, et al. Among authors: lattanzi m. Clin Cancer Res. 2023 Nov 14;29(22):4586-4595. doi: 10.1158/1078-0432.CCR-23-1283. Clin Cancer Res. 2023. PMID: 37682528
Fully Liquid MenACWY-CRM Vaccine: Results from an Integrated Safety Analysis.
Vir Singh P, Tiberi P, Di Domenico GF, Romolini V, Mzolo T, Costantini M, Akhund T, Basile V, Lattanzi M, Pellegrini M. Vir Singh P, et al. Among authors: lattanzi m. Drug Saf. 2023 Jan;46(1):99-108. doi: 10.1007/s40264-022-01242-8. Epub 2022 Nov 11. Drug Saf. 2023. PMID: 36369456 Free PMC article.
Reply to S. Zhang.
Lattanzi M, Funt SA, Rosenberg JE. Lattanzi M, et al. J Clin Oncol. 2022 Aug 10;40(23):2657-2658. doi: 10.1200/JCO.22.00809. Epub 2022 May 24. J Clin Oncol. 2022. PMID: 35609227 No abstract available.
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, Apollo A, Durdin TD, Truong H, Kamradt J, Khalil M, Lash B, Ostrovnaya I, McCoy AS, Hettich G, Regazzi A, Jihad M, Ratna N, Boswell A, Francese K, Yang Y, Folefac E, Herr HW, Donat SM, Pietzak E, Cha EK, Donahue TF, Goh AC, Huang WC, Bajorin DF, Iyer G, Bochner BH, Balar AV, Mortazavi A, Rosenberg JE. Funt SA, et al. Among authors: lattanzi m. J Clin Oncol. 2022 Apr 20;40(12):1312-1322. doi: 10.1200/JCO.21.01485. Epub 2022 Jan 28. J Clin Oncol. 2022. PMID: 35089812 Free PMC article. Clinical Trial.
83 results